About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation

NCT01102114·25 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Nabi Biopharmaceuticals

Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Current smoker who smokes at least 10 cigarettes a day during the past year and wants to quit smoking.
Smokers who are in good general health.

You may not be if

Prior exposure to NicVAX or any other nicotine vaccine.
Use of systemic steroids.
Cancer or cancer treatment in the last 5 years.
HIV infection.
History of drug or alcohol abuse or dependence within 12 months.
Significant cardiovascular, hepatic, renal, psychiatric and/or respiratory disease.
Inability to fulfill all visits for approximately 52 weeks.

The record

StatusCompleted

PhasePhase 3

Taking part1,000

StartedMar 2010

UpdatedMay 9, 2012

Conditions

Smoking Cessation

Where25

NicVAX Investigator
Encino, California, United States
NicVAX Investigator
Los Alamitos, California, United States
NicVAX Investigator
Denver, Colorado, United States

Clareo Health | A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation